Pascal Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSCBF research report →
Companywww.pascalbiosciences.com
Pascal Biosciences Inc. , a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment.
- CEO
- John Kueber
- IPO
- 2015
- Employees
- 2
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $4.20M
- P/E
- -4.21
- P/S
- 0.68
- P/B
- 1.19
- EV/EBITDA
- -42.85
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 41.28%
- Op Margin
- -16.96%
- Net Margin
- -16.21%
- ROE
- -23.66%
- ROIC
- -23.72%
Growth & Income
- Revenue
- $670.16K · 0.00%
- Net Income
- $-398,945.11 · 17.35%
- EPS
- $-0.02 · 54.05%
- Op Income
- $-895,844.9
- FCF YoY
- -162.53%
Performance & Tape
- 52W High
- $0.15
- 52W Low
- $0.02
- 50D MA
- $0.10
- 200D MA
- $0.09
- Beta
- -0.01
- Avg Volume
- 20.43K
Get TickerSpark's AI analysis on PSCBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PSCBF Coverage
We haven't published any research on PSCBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PSCBF Report →